WuXi begins construction on $150m disposable biomanufacturing site in China

By Zachary Brennan

- Last updated on GMT

WuXi begins construction on $150m disposable biomanufacturing site in China
WuXi PharmaTech subsidiary WuXi Biologics has begun construction on a new $150m biologics manufacturing facility in Wuxi, China, which is expected to be the largest mammalian cell culture manufacturing sire using disposable bioreactors in the world.

To be completed by January 2017, the new facility will also be the largest biologics manufacturing facility in China. This added capacity will support WuXi's biologics manufacturing pipeline in the near term.

The new facility will house fourteen 2000L disposable bioreactors for fed-batch cell culture and two 1000L bioreactors for perfusion runs. The facility will also be built to run advanced continuous or semi-continuous manufacturing processes in addition to traditional fed-batch and perfusion modes. 

This facility further expands WuXi's biologics manufacturing capabilities, which also includes biologics clinical drug substance and drug product manufacturing facilities in Wuxi city, which meet cGMP standards of the US, EU and China.

 Ge Li, Chairman and CEO of WuXi PharmaTech, who recently put forth a bid to take the contract developer and manufacturer private​, noted: "This project continues to strengthen WuXi's capabilities in integrated biologics discovery, development, and manufacturing services. We maintain the highest quality standards to expedite global development of biologics for both international clients and Chinese companies​."

Related news

Show more

Related products

show more

Reliability, scale, and security of supply

Reliability, scale, and security of supply

Content provided by Univar Solutions USA | 28-Aug-2024 | Product Brochure

Univar Solutions Pharmaceutical Ingredients is proud to offer one of the most expansive portfolios of 15,000+ products, including high-purity solvents,...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us

Products

View more

Webinars